tiprankstipranks
Trending News
More News >
JD Health International, Inc. (HK:6618)
:6618
Hong Kong Market
Advertisement

JD Health International, Inc. (6618) AI Stock Analysis

Compare
19 Followers

Top Page

HK:6618

JD Health International, Inc.

(6618)

Rating:76Outperform
Price Target:
HK$75.00
▲(17.46% Upside)
JD Health International, Inc. demonstrates strong financial performance and positive earnings call sentiment, driving a high overall score. Technical indicators show strong momentum but suggest caution due to overbought conditions. The high P/E ratio indicates potential overvaluation, slightly tempering the overall score.

JD Health International, Inc. (6618) vs. iShares MSCI Hong Kong ETF (EWH)

JD Health International, Inc. Business Overview & Revenue Model

Company DescriptionJD Health International, Inc. (6618) is a leading online healthcare platform in China, leveraging technology to provide comprehensive healthcare solutions. It operates in sectors such as online pharmacy, medical consultation, and health management. The company offers core services including online medical consultations, a wide range of pharmaceutical and healthcare products, and personalized wellness programs, aiming to improve accessibility to healthcare services for consumers across China.
How the Company Makes MoneyJD Health International, Inc. generates revenue primarily through its online pharmacy platform, which sells a vast array of pharmaceutical and healthcare products directly to consumers. The company also earns income by offering online medical consultation services, where users can pay for virtual consultations with healthcare professionals. Additionally, JD Health leverages its platform to offer health management services and personalized wellness programs, contributing to its revenue streams. Strategic partnerships with hospitals, clinics, and pharmaceutical companies further enhance its service offerings and expand its customer base, driving additional revenue growth.

JD Health International, Inc. Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Mar 30, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong overall performance by JD Health, with significant revenue and active user growth, expansion in AI applications, and innovation in health care services. These positive aspects significantly outweigh the relatively minor increase in selling and marketing expenses, highlighting a positive outlook for the company.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
JD Health achieved revenue of RMB 35.3 billion in the first half of 2025, up 24.5% year-over-year.
Increase in Active Users
Annual active user accounts reached 200 million, a net addition of approximately 20 million compared to June 30, 2024.
Expansion of AI Applications
AI Jingyi intelligent agents served over 50 million users, with significant improvements in user service rate and diagnostic efficiency.
Growth in Service Revenue
Service revenue reached RMB 6.0 billion, representing growth of 34.4% year-over-year.
Innovation in Health Care Services
JD Health expanded its online hospital specialty care services and optimized home care on-demand service ecosystem.
Negative Updates
Increased Selling and Marketing Expenses
Selling and marketing expenses rose by RMB 420 million year-over-year, increasing the expense ratio by 20 basis points.
Company Guidance
During the JD Health International Corporation's 2025 interim results call, the company provided guidance on its business performance and future strategies, highlighting several key metrics. JD Health reported a 24.5% year-over-year increase in revenue, reaching RMB 35.3 billion for the first half of 2025. The company's direct sales revenue constituted 83.1% of total revenue, with a 22.7% year-over-year increase to RMB 29.3 billion. Service revenue grew by 34.4% to RMB 6.0 billion, accounting for 16.9% of the total revenue. JD Health's annual active user accounts reached 200 million, a net addition of 20 million compared to the previous year. The company continues to enhance its supply chain advantages and omnichannel model to improve user experience and accessibility. Additionally, JD Health is leveraging AI technologies, with AI Jingyi serving over 50 million users, enhancing service efficiency and user experience. The company aims to further integrate AI into its operations while exploring new business models like on-demand retail to drive future growth.

JD Health International, Inc. Financial Statement Overview

Summary
JD Health International, Inc. presents a compelling financial profile with strong revenue growth, improved profitability, and a stable balance sheet. The company has effectively managed its debt levels, ensuring financial stability. Cash flow generation remains robust, supporting its operations and growth initiatives.
Income Statement
85
Very Positive
JD Health International, Inc. has demonstrated strong revenue growth over the years, with a notable increase from 2019 to 2024. Gross profit margins have remained healthy, reflecting efficient cost management. The net profit margin has improved significantly, turning from losses in earlier years to profitable outcomes in recent periods, showcasing strong profitability. EBIT and EBITDA margins have shown positive trends, indicating enhanced operational efficiency.
Balance Sheet
80
Positive
The company's balance sheet is robust, characterized by a high equity ratio, which indicates strong financial stability and low reliance on debt. The debt-to-equity ratio is low, suggesting prudent financial management and reduced financial risk. Return on equity has improved significantly, reflecting better utilization of shareholders' funds.
Cash Flow
78
Positive
JD Health International exhibits a solid cash flow position, with consistent operating cash flow generation. Free cash flow growth has been positive, indicating strong cash generation capabilities. The operating cash flow to net income ratio is healthy, underscoring efficient cash conversion. However, a slight decline in operating cash flow compared to the previous year is a point of concern.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue58.16B53.53B46.74B30.68B19.38B
Gross Profit13.31B11.87B9.89B7.20B4.92B
EBITDA1.31B2.93B-60.93M-1.37B364.50M
Net Income4.16B2.14B380.11M-1.07B-17.23B
Balance Sheet
Total Assets71.27B64.29B61.28B48.00B43.99B
Cash, Cash Equivalents and Short-Term Investments51.24B41.22B47.67B41.99B40.30B
Total Debt258.39M214.75M199.41M201.27M89.98M
Total Liabilities16.03B14.92B16.49B8.15B4.74B
Stockholders Equity55.23B49.36B44.78B39.85B39.25B
Cash Flow
Free Cash Flow4.29B4.54B5.86B2.93B3.68B
Operating Cash Flow4.33B4.60B5.91B3.43B3.70B
Investing Cash Flow3.15B-8.02B-4.24B-17.75B-7.84B
Financing Cash Flow-45.61M-117.20M-925.45M-163.65M32.03B

JD Health International, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price63.85
Price Trends
50DMA
52.88
Positive
100DMA
46.05
Positive
200DMA
38.61
Positive
Market Momentum
MACD
3.29
Positive
RSI
64.13
Neutral
STOCH
60.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6618, the sentiment is Positive. The current price of 63.85 is above the 20-day moving average (MA) of 62.05, above the 50-day MA of 52.88, and above the 200-day MA of 38.61, indicating a bullish trend. The MACD of 3.29 indicates Positive momentum. The RSI at 64.13 is Neutral, neither overbought nor oversold. The STOCH value of 60.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6618.

JD Health International, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
HK$204.41B39.538.52%18.56%79.54%
70
Outperform
HK$675.48M8.185.33%7.92%0.47%50.46%
66
Neutral
HK$1.64B5.6420.47%4.37%-3.56%-17.45%
65
Neutral
HK$7.73B20.7714.86%1.25%16.41%32.97%
65
Neutral
HK$8.96B18.226.78%-13.92%-36.32%
60
Neutral
HK$7.52B28.12-9.67%2.17%-8.56%-403.12%
51
Neutral
$7.95B-0.40-42.50%2.21%22.29%-1.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6618
JD Health International, Inc.
63.85
39.85
166.04%
HK:1526
Rici Healthcare Holdings Ltd.
1.03
-0.03
-2.83%
HK:1951
Jinxin Fertility Group Ltd.
2.74
0.52
23.42%
HK:2273
Gushengtang Holdings Limited
32.76
-2.50
-7.09%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
2.02
-0.23
-10.22%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
14.58
-1.04
-6.66%

JD Health International, Inc. Corporate Events

JD Health Reports Strong Growth in H1 2025, Driven by AI and Healthcare Innovations
Aug 14, 2025

JD Health International, Inc. announced its interim results for the first half of 2025, reporting significant financial growth with a 24.5% increase in revenue to RMB35.3 billion and a 27.4% rise in profit to RMB2.59 billion. The company has improved its healthcare offerings and advanced AI-enhanced service models, reinforcing its leading position in the healthcare market and addressing the growing demand for high-quality healthcare services. The company’s strategic focus on AI and health consumption aligns with China’s policies promoting high-quality healthcare development, further solidifying its market position.

JD Health International Schedules Board Meeting to Approve Interim Results
Jul 31, 2025

JD Health International Inc. has announced a board meeting scheduled for August 14, 2025, to approve and publish its unaudited interim results for the first half of 2025. The meeting will also consider the recommendation for an interim dividend. The company will host a conference call on the same day to discuss these results, indicating a proactive approach in engaging with stakeholders and maintaining transparency in its financial operations.

JD Health Grants Over 800,000 Award Shares to Employees
Jul 1, 2025

JD Health International, Inc. announced the grant of 834,433 Award Shares to its employees under the Post-IPO Share Award Scheme, representing approximately 0.03% of the total issued shares. The shares will vest over various periods ranging from 0.25 to 4 years, with no performance targets attached. This move aims to incentivize employees and align their interests with the company’s growth, potentially enhancing employee retention and satisfaction.

JD Health International Secures Shareholder Approval at AGM
Jun 20, 2025

JD Health International, Inc. announced the successful passing of all proposed resolutions at its Annual General Meeting held on June 20, 2025. The resolutions included the adoption of financial statements, re-election of directors, and granting of mandates for share issuance and repurchase. This outcome reflects strong shareholder support and positions the company for continued strategic initiatives and governance stability.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025